ClinicalTrials.gg
TerminatedNCT01257542Updated Sep 20, 2012Results posted

Acute Cough Study In Children

A Phase 4 interventional study of Dextromethorphan and Placebo in Common Cold and Infections, Upper Respiratory Tract, sponsored by Pfizer. Terminated at 4 sites in United States. Open to participants aged 6 Years to 11 Years. Per ClinicalTrials.gov, last updated 2012-09-20.

Sponsored by Pfizer · Phase 4, Interventional, and Treatment

Why this study was terminated
See termination reason in detailed description.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
140
Allocation
Randomized
Ages
6 Years to 11 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 47 studies in Common Cold with a site in United States — 7 open to participants now, 8 under way, none of them phase 3. Common Cold · United States.

Enrollment
26th of 40
140 · median 228
Started
2010
with 3 others
Phase 4
3 of 47
none open now
Registered
20th of 47
by date

Among the 47 studies in Common Cold with a site in United States, this one is the 26th largest by enrollment of the 40 interventional ones that give a count, is one of 4 that started in 2010, is one of 3 in phase 4, and was the 20th registered.

Common Cold

219 studies on the registry are indexed under Common Cold; 23 are open to participants now.

Browse Common Cold studies →

Open to participants now

7 of the 47 studies in Common Cold with a site in United States are open now. Recruiting first, the newest first:

2 more — sign in →

All 7 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 14 Common Cold studies recruiting now, 4 (29%) set no upper age limit and 9 (64%) stop at 75 or younger; 4 take children under 18; 7 take healthy volunteers.

This study: 6 Years to 11 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 47 studies in Common Cold with a site in United States, or all of them as a file.
02

Study summary

15 mg dextromethorphan hydrobromide will be better than placebo with respect to reducing the number of coughs over 6 hours and reducing the subjective severity of cough over 6 hours.

Read the detailed description

In light of protocol changes required due to methodological and operational issues, including background noise in cough recordings which could impact data interpretation, the study has been terminated.

03

Conditions studied

  • Common Cold
  • Infections, Upper Respiratory Tract

Keywords

  • randomized
  • parallel
  • double-blind
  • placebo-controlled
  • cough
  • efficacy
  • safety
  • dextromethorphan
04

Who can participate

Ages eligible
6 Years to 11 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Male or female healthy children ages 6 to under 12 years who are symptomatic with a cough due to a cold or acute URTI characterized by:

  • Onset of cold/URTI symptoms occurring no more than 10 days prior to Visit 1;
  • At least 5 coughs during the second 30-minute period of the 60-minute baseline period.

General good health, aside from a common cold, and has no to the study or rescue medication

Exclusion criteria

Exclusion Criteria:

  • Acute, subchronic, or chronic cough due to any other condition other than a common cold

History of cardiovascular, pulmonary, hepatic, renal, neurological, hematological, , psychiatric, metabolic, gastro-intestinal or endocrine disease

Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
140 participants (actual)

Study arms

  • Experimental
    Active

    Drug: Dextromethorphan

  • Placebo comparator
    Placebo

    Drug: Placebo

Interventions

  • A single 10 mL dose of Children's Triaminic Syrup (Dextromethorphan Hydrobromide 7.5 mg per 5 mL (total dose of 15 mg)

  • DrugPlacebo

    A single 10 mL dose of matching placebo syrup

06

What researchers measure

Primary outcomes

  1. Total Cough Count

    Total cough count was done by trained assessors using continuous digital video and audio recordings.

    Time frame: Up to 6 hours post-dose

Secondary outcomes

  1. Change From Baseline in Perceived Verbal Cough Severity Scale for 6 Hour Post-Dose Period

    Perceived verbal cough severity score was assessed on a 5-point categorical rating scale in accordance to the question "How much have you coughed in the last hour?", where 0 = not at all, 1 = a tiny bit, 2 = a little, 3 = some and 4 = a lot. The change from baseline over the 6-hour post-dosing period calculated as the average of change from baseline \[that is (i.e.) baseline value minus the post baseline value\] measurements of Hour 1 to Hour 6, thus the change from baseline ranged from -4 to 4; higher score indicated a better improvement.

    Time frame: Baseline, 1, 2, 3, 4, 5, 6 hours post-dose

  2. Change From Baseline in Verbal Cough Severity Scale at Hours 1, 2, 3, 4, 5 and 6

    Verbal cough severity score was assessed on a 5-point categorical rating scale in accordance to the question "How much have you coughed in the last hour?", where 0 = not at all, 1 = a tiny bit, 2 = a little, 3 = some and 4 = a lot. The change from baseline values were derived by subtracting each post baseline value from the baseline value, and ranged from -4 to 4; higher score indicated a better improvement.

    Time frame: Baseline, 1, 2, 3, 4, 5, 6 hours

  3. Change From Baseline in Perceived Numerical Cough Severity Scale for 6 Hour Post-Dose Period

    Perceived numerical cough severity score was assessed on an 11-point categorical rating scale in accordance to the question "How much have you coughed in the last hour?", where 0 = did not cough at all and 10 = cough a lot. The change from baseline for the 6-hour post-dosing period was calculated as the average of change from baseline (i.e. baseline value minus the post baseline value) measurements of Hour 1 to Hour 6, thus the change from baseline values ranged from -10 to 10; higher score indicated a better improvement.

    Time frame: Baseline, 1, 2, 3, 4, 5, 6 hour post-dose

  4. Change From Baseline in Numerical Cough Severity Scale at Hours 1, 2, 3, 4, 5 and 6

    Numerical cough severity score was assessed on an 11-point categorical rating scale in accordance to the question "How much have you coughed in the last hour?", wherein 0 = did not cough at all and 10 = cough a lot. The change from baseline was derived by subtracting the post baseline value from the baseline value and ranged from -10 to 10; higher score indicated a better improvement.

    Time frame: Baseline, 1, 2, 3, 4, 5, 6 hours

  5. Participants' Global Assessment of Cough: Cough Severity

    Participant global assessment of cough with the assistance of parent or legal guardian was scored on a 5-point categorical scale based on response to the question " How much have you coughed in the past 6 hours?" where 0 = not at all, 1 = a tiny bit, 2 = a little, 3 = some and 4 = a lot.

    Time frame: Within 5 minutes after Hour 6

  6. Participants' Global Assessment of Cough: Relief From Cough

    Participant global assessment of cough with the assistance of parent or legal guardian was scored on a 5-point categorical scale based on response to the question "From when you woke up this morning until now, how much better is your cough?" where 0 = not at all better, 1 = a tiny bit better, 2 = a little better, 3 = better and 4 = a lot better.

    Time frame: Within 5 minutes after Hour 6

07

Results

Posted Sep 20, 2012
Limitations and caveats
Due to methodological issues during study conduct, the study was terminated after only less than 50% of the targeted enrollment was achieved.

Participant flow

Participant flow — Overall Study
MilestonePlaceboDextromethorphan Hydrobromide
Started5552
Completed5245
Not completed37
Withdrew: Protocol violation35
Withdrew: Withdrawal by subject02

Outcome measures

PrimaryTotal Cough Count

Total cough count was done by trained assessors using continuous digital video and audio recordings.

Time frame:
Up to 6 hours post-dose
Reported as:
Mean · Cough counts
Total Cough Count
Cough countsPlaceboDextromethorphan Hydrobromide
Total Cough Count238.7 ± 252.3190.9 ± 190.6
Statistical analysis
  • Placebo vs Dextromethorphan Hydrobromide · Negative binomial regression · p = 0.252 (p-value was calculated using negative binomial regression model with treatment, site and baseline of cough count terms with log (exposure time) as the offset parameter.) · Odds ratio (or): 0.83 · 95% CI 0.59 to 1.15
SecondaryChange From Baseline in Perceived Verbal Cough Severity Scale for 6 Hour Post-Dose Period

Perceived verbal cough severity score was assessed on a 5-point categorical rating scale in accordance to the question "How much have you coughed in the last hour?", where 0 = not at all, 1 = a tiny bit, 2 = a little, 3 = some and 4 = a lot. The change from baseline over the 6-hour post-dosing period calculated as the average of change from baseline \[that is (i.e.) baseline value minus the post baseline value\] measurements of Hour 1 to Hour 6, thus the change from baseline ranged from -4 to 4; higher score indicated a better improvement.

Time frame:
Baseline, 1, 2, 3, 4, 5, 6 hours post-dose
Reported as:
Mean · Units on a scale
Change From Baseline in Perceived Verbal Cough Severity Scale for 6 Hour Post-Dose Period
Units on a scalePlaceboDextromethorphan Hydrobromide
Baseline3.0 ± 0.92.9 ± 0.9
Change for 6 hour post-dose period1.3 ± 1.11.1 ± 1.1
Statistical analysis
  • Placebo vs Dextromethorphan Hydrobromide · ANOVA · p = 0.134 (p-value was calculated using ANOVA model with treatment, site and baseline cough severity verbal rating scale terms.) · Ls mean difference: -0.26 · 95% CI -0.60 to 0.08
SecondaryChange From Baseline in Verbal Cough Severity Scale at Hours 1, 2, 3, 4, 5 and 6

Verbal cough severity score was assessed on a 5-point categorical rating scale in accordance to the question "How much have you coughed in the last hour?", where 0 = not at all, 1 = a tiny bit, 2 = a little, 3 = some and 4 = a lot. The change from baseline values were derived by subtracting each post baseline value from the baseline value, and ranged from -4 to 4; higher score indicated a better improvement.

Time frame:
Baseline, 1, 2, 3, 4, 5, 6 hours
Reported as:
Mean · Units on a scale
Change From Baseline in Verbal Cough Severity Scale at Hours 1, 2, 3, 4, 5 and 6
Units on a scalePlaceboDextromethorphan Hydrobromide
Change at 1 hour1.0 ± 1.20.9 ± 1.2
Change at 2 hours1.2 ± 1.20.9 ± 1.4
Change at 3 hours1.3 ± 1.20.9 ± 1.4
Change at 4 hours1.4 ± 1.31.1 ± 1.4
Change at 5 hours1.7 ± 1.31.2 ± 1.4
Change at 6 hours1.5 ± 1.41.2 ± 1.4
Statistical analysis
  • Placebo vs Dextromethorphan Hydrobromide · ANOVA · p = 0.768 (p-value was calculated using ANOVA model with treatment, site and baseline cough severity verbal rating scale terms.) · Ls mean difference: -0.06 · 95% CI -0.45 to 0.33
  • Placebo vs Dextromethorphan Hydrobromide · ANOVA · p = 0.358 (p-value was calculated using ANOVA model with treatment, site and baseline cough severity verbal rating scale terms.) · Ls mean difference: -0.20 · 95% CI -0.64 to 0.23
  • Placebo vs Dextromethorphan Hydrobromide · ANOVA · p = 0.139 (p-value was calculated using ANOVA model with treatment, site and baseline cough severity verbal rating scale terms.) · Ls mean difference: -0.32 · 95% CI -0.74 to 0.10
  • Placebo vs Dextromethorphan Hydrobromide · ANOVA · p = 0.364 (p-value was calculated using ANOVA model with treatment, site and baseline cough severity verbal rating scale terms.) · Ls mean difference: -0.21 · 95% CI -0.68 to 0.25
  • Placebo vs Dextromethorphan Hydrobromide · ANOVA · p = 0.039 (p-value was calculated using ANOVA model with treatment, site and baseline cough severity verbal rating scale terms.) · Ls mean difference: -0.46 · 95% CI -0.90 to -0.02
  • Placebo vs Dextromethorphan Hydrobromide · ANOVA · p = 0.206 (p-value was calculated using ANOVA model with treatment, site and baseline cough severity verbal rating scale terms.) · Ls mean difference: -0.29 · 95% CI -0.75 to 0.16
SecondaryChange From Baseline in Perceived Numerical Cough Severity Scale for 6 Hour Post-Dose Period

Perceived numerical cough severity score was assessed on an 11-point categorical rating scale in accordance to the question "How much have you coughed in the last hour?", where 0 = did not cough at all and 10 = cough a lot. The change from baseline for the 6-hour post-dosing period was calculated as the average of change from baseline (i.e. baseline value minus the post baseline value) measurements of Hour 1 to Hour 6, thus the change from baseline values ranged from -10 to 10; higher score indicated a better improvement.

Time frame:
Baseline, 1, 2, 3, 4, 5, 6 hour post-dose
Reported as:
Mean · Units on a scale
Change From Baseline in Perceived Numerical Cough Severity Scale for 6 Hour Post-Dose Period
Units on a scalePlaceboDextromethorphan Hydrobromide
Baseline6.8 ± 2.27.0 ± 2.3
Change for 6 hour post-dose period2.8 ± 2.52.5 ± 3.1
Statistical analysis
  • Placebo vs Dextromethorphan Hydrobromide · ANOVA · p = 0.304 (p-value was calculated using ANOVA model with treatment, site and baseline cough severity numerical rating scale terms.) · Ls mean difference: -0.49 · 95% CI -1.43 to 0.45
SecondaryChange From Baseline in Numerical Cough Severity Scale at Hours 1, 2, 3, 4, 5 and 6

Numerical cough severity score was assessed on an 11-point categorical rating scale in accordance to the question "How much have you coughed in the last hour?", wherein 0 = did not cough at all and 10 = cough a lot. The change from baseline was derived by subtracting the post baseline value from the baseline value and ranged from -10 to 10; higher score indicated a better improvement.

Time frame:
Baseline, 1, 2, 3, 4, 5, 6 hours
Reported as:
Mean · Units on a scale
Change From Baseline in Numerical Cough Severity Scale at Hours 1, 2, 3, 4, 5 and 6
Units on a scalePlaceboDextromethorphan Hydrobromide
Change at 1 hour2.0 ± 2.92.0 ± 2.8
Change at 2 hours2.5 ± 2.62.1 ± 3.5
Change at 3 hours2.7 ± 2.72.3 ± 3.5
Change at 4 hours2.9 ± 2.82.5 ± 3.6
Change at 5 hours3.6 ± 2.83.0 ± 3.2
Change at 6 hours3.4 ± 3.32.8 ± 3.8
Statistical analysis
  • Placebo vs Dextromethorphan Hydrobromide · ANOVA · p = 0.954 (p-value was calculated using ANOVA model with treatment, site and baseline cough severity numerical rating scale terms.) · Ls mean difference: -0.03 · 95% CI -1.03 to 0.97
  • Placebo vs Dextromethorphan Hydrobromide · ANOVA · p = 0.426 (p-value was calculated using ANOVA model with treatment, site and baseline cough severity numerical rating scale terms.) · Ls mean difference: -0.44 · 95% CI -1.54 to 0.65
  • Placebo vs Dextromethorphan Hydrobromide · ANOVA · p = 0.396 (p-value was calculated using ANOVA model with treatment, site and baseline cough severity numerical rating scale terms.) · Ls mean difference: -0.45 · 95% CI -1.49 to 0.60
  • Placebo vs Dextromethorphan Hydrobromide · ANOVA · p = 0.402 (p-value was calculated using ANOVA model with treatment, site and baseline cough severity numerical rating scale terms.) · Ls mean difference: -0.49 · 95% CI -1.63 to 0.66
  • Placebo vs Dextromethorphan Hydrobromide · ANOVA · p = 0.204 (p-value was calculated using ANOVA model with treatment, site and baseline cough severity numerical rating scale terms.) · Ls mean difference: -0.69 · 95% CI -1.75 to 0.38
  • Placebo vs Dextromethorphan Hydrobromide · ANOVA · p = 0.179 (p-value was calculated using ANOVA model with treatment, site and baseline cough severity numerical rating scale terms.) · Ls mean difference: -0.84 · 95% CI -2.06 to 0.39
SecondaryParticipants' Global Assessment of Cough: Cough Severity

Participant global assessment of cough with the assistance of parent or legal guardian was scored on a 5-point categorical scale based on response to the question " How much have you coughed in the past 6 hours?" where 0 = not at all, 1 = a tiny bit, 2 = a little, 3 = some and 4 = a lot.

Time frame:
Within 5 minutes after Hour 6
Reported as:
Mean · Units on a scale
Participants' Global Assessment of Cough: Cough Severity
Units on a scalePlaceboDextromethorphan Hydrobromide
Participants' Global Assessment of Cough: Cough Severity3.1 ± 0.93.0 ± 1.3
Statistical analysis
  • Placebo vs Dextromethorphan Hydrobromide · Cochran-Mantel-Haenszel · p = 0.523 (p-value was calculated from the Cochran-Mantel-Haenszel (CMH) test with modified ridit scores controlling site.) · Mean difference (final values): 0.09 · 95% CI -0.21 to 0.39
SecondaryParticipants' Global Assessment of Cough: Relief From Cough

Participant global assessment of cough with the assistance of parent or legal guardian was scored on a 5-point categorical scale based on response to the question "From when you woke up this morning until now, how much better is your cough?" where 0 = not at all better, 1 = a tiny bit better, 2 = a little better, 3 = better and 4 = a lot better.

Time frame:
Within 5 minutes after Hour 6
Reported as:
Mean · Units on a scale
Participants' Global Assessment of Cough: Relief From Cough
Units on a scalePlaceboDextromethorphan Hydrobromide
Participants' Global Assessment of Cough: Relief From Cough2.9 ± 1.02.7 ± 1.3
Statistical analysis
  • Placebo vs Dextromethorphan Hydrobromide · Cochran-Mantel-Haenszel · p = 0.796 (p-value was calculated from the CMH test with modified ridit scores controlling site.) · Mean difference (final values): -0.06 · 95% CI -0.35 to 0.24

Adverse events

Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo—0/55 (0%)4/55 (7.3%)
Dextromethorphan Hydrobromide—0/52 (0%)6/52 (11.5%)
Most frequent other events
Most frequent other events
EventPlaceboDextromethorphan Hydrobromide
HeadacheNervous system disorders0/553/52
NauseaGastrointestinal disorders0/552/52
PyrexiaGeneral disorders2/550/52
VomitingGastrointestinal disorders0/551/52
Limb injuryInjury, poisoning and procedural complications0/551/52
Skin lacerationInjury, poisoning and procedural complications0/551/52
DizzinessNervous system disorders0/551/52
Abdominal pain upperGastrointestinal disorders1/550/52
ChokingRespiratory, thoracic and mediastinal disorders1/550/52

Baseline characteristics

Age Continuous
Age Continuous(Years)PlaceboDextromethorphan HydrobromideTotal
Mean8.9 ± 1.88.9 ± 1.68.9 ± 1.7
Sex: Female, Male
Sex: Female, Male(Participants)PlaceboDextromethorphan HydrobromideTotal
Female322557
Male232750
08

Study locations

4 sites
  • DMI Research
    Pinellas, Florida 33782-4533, United States
  • Concentrics Center for Research
    Indianapolis, Indiana 46240, United States
  • Cyn3rgy Research
    Gresham, Oregon 97030, United States
  • Clinical Research Associates Incorporated
    Nashville, Tennessee 37203, United States
09

References and documents

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Dec 2010, a primary completion of Mar 2011 and a completion of Mar 2011. It does not say whether these dates are actual or estimated.

Results were first posted in Sep 2012, 1 year 6 months after primary completion. A results delay was requested in Feb 2012.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 7, 2010
First posted
Dec 9, 2010
Start
Dec 2010
Primary completionActual
Mar 2011
CompletionActual
Mar 2011
Results delay requested
Feb 15, 2012
Results first posted
Sep 20, 2012
Last update
Sep 20, 2012
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 20, 2012, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01257542
Lead sponsor
Pfizer
Responsible party
Sponsor
First posted
Dec 9, 2010
Start date
Dec 2010
Primary completion
Mar 2011
Completion
Mar 2011
Results posted
Sep 20, 2012
Last update
Sep 20, 2012

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Aug 2012. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Dextromethorphan

Start the discussion